Corporate News Report

AbbVie Announces Positive Phase III Results for Subcutaneous SKYRIZI® in Crohn’s Disease

AbbVie disclosed clinical data for its subcutaneous formulation of SKYRIZI® (risankizumab‑rzaa) at the American College of Gastroenterology’s (ACG) annual meeting. The Phase III AFFIRM study, a randomized, double‑blind, placebo‑controlled trial, enrolled 289 adults with moderately to severely active Crohn’s disease. Patients received a subcutaneous induction regimen of risankizumab‑rzaa, followed by maintenance dosing, and were compared with a placebo cohort.

Efficacy Outcomes

  • Endoscopic Remission: The subcutaneous induction group achieved a statistically significant higher rate of endoscopic remission (defined as a Crohn’s Disease Endoscopic Index of Severity score ≤2) than placebo. The remission rate was 38.7 % versus 12.3 % (p < 0.001).
  • Ulcer‑Free Endoscopy: Rates of ulcer‑free endoscopy were also superior, with 35.1 % of the risankizumab‑rzaa group versus 10.5 % in the placebo arm (p < 0.001).
  • Treatment‑Naïve Subgroup: Notably, patients who had not previously received advanced biologic or small‑molecule therapy experienced remission rates of 42.9 % and ulcer‑free rates of 38.5 %, exceeding those observed in treatment‑experienced participants.

These efficacy endpoints align with the primary objectives of the AFFIRM study and demonstrate that the subcutaneous dosing schedule provides clinically meaningful benefit in a real‑world Crohn’s disease population.

Safety Profile

The safety data for the subcutaneous formulation were consistent with the known profile of risankizumab:

  • Adverse Events (AEs): Overall incidence of treatment‑emergent AEs was 27.4 % in the risankizumab‑rzaa arm versus 22.8 % in placebo.
  • Serious AEs: Serious adverse events occurred in 2.7 % of risankizumab‑rzaa patients and 1.5 % of placebo patients.
  • Infections: Incidence of serious infections was 0.7 % in the risankizumab‑rzaa group, with no opportunistic infections reported.
  • Injection Site Reactions: Mild injection site reactions were observed in 4.5 % of patients, all of which resolved without intervention.

The safety results support the tolerability of the subcutaneous route and suggest a manageable risk profile for clinicians considering this modality.

Regulatory Implications

The AFFIRM data bolster AbbVie’s regulatory strategy for a subcutaneous induction dosing strategy. Key points for potential approval pathways include:

  1. Indication Expansion: Demonstrated efficacy in both treatment‑naïve and treatment‑experienced cohorts may support labeling that encompasses a broader patient population.
  2. Route of Administration: Subcutaneous delivery offers an advantage over intravenous infusions in terms of patient convenience and healthcare resource utilization.
  3. Post‑Approval Commitments: AbbVie may need to provide post‑marketing safety surveillance data, especially concerning long‑term safety in biologic‑naïve patients.

Regulatory agencies will likely scrutinize the comparative efficacy data against existing anti‑IL‑23 agents and evaluate the clinical benefit versus cost.

Market and Share Price Impact

Following the presentation of AFFIRM results, AbbVie’s shares declined by approximately 2 % at market close, before a modest after‑hours rebound. The broader healthcare sector recorded a small decline on the same day, while energy stocks appreciated. This market movement reflects:

  • Investor Sentiment: A cautious stance on biotech earnings amid a general market rotation toward energy.
  • Valuation Considerations: AbbVie’s valuation remains attractive relative to peers, yet the disclosure of new data may have prompted a short‑term reevaluation.
  • Strategic Focus: The company’s sustained pipeline in immune‑mediated diseases, coupled with the positive SKYRIZI data, supports long‑term growth expectations.

Healthcare professionals and payers should anticipate that the availability of a subcutaneous induction option may influence formulary decisions and reimbursement models, potentially affecting patient access and health‑system cost structures.

Practical Implications for Patient Care

  • Treatment Selection: Clinicians may consider risankizumab‑rzaa for patients requiring a less resource‑intensive induction method, especially those who are biologic‑naïve.
  • Monitoring: Given the favorable safety profile, routine monitoring remains aligned with existing guidelines for anti‑IL‑23 therapies.
  • Patient Education: The subcutaneous route offers a patient‑friendly option that may improve adherence and satisfaction.

In summary, AbbVie’s AFFIRM study provides robust evidence for the subcutaneous induction of SKYRIZI® in Crohn’s disease, reinforcing its therapeutic positioning and informing future regulatory and market strategies.